Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.
Muhammad Nasir KalamMuhammad Fawad RasoolFaleh AlqahtaniImran ImranAsim Ur RehmanNaveed AhmadPublished in: Drug design, development and therapy (2021)
The developed PBPK model has successfully described propranolol PK in healthy and cirrhosis populations after IV and oral administration. The evaluated PBPK propranolol-cirrhosis model can have many implications in predicting propranolol dosing in liver cirrhosis patients with different stages of disease severity.